Efficacy and long‐term immunogenicity of hepatitis B vaccine in haemodialysis patients

Background:  Hepatitis B vaccine is effective in protection against hepatitis B virus (HBV) infection in haemodialysis (HD) patients, but the antibody response is variable in this population and the persistence of immunity in them remains largely unknown. In this study we aimed to evaluate the efficacy and long‐term immunogenicity of hepatitis B vaccine in HD patients.

[1]  B. Nowakowska,et al.  Influence of genetic factors on the susceptibility to HBV infection, its clinical pictures, and responsiveness to HBV vaccination. , 2005, Archivum immunologiae et therapiae experimentalis.

[2]  V. Kovačić,et al.  [Does efficient haemodialysis improve the response to hepatitis B virus vaccination?]. , 2004, Lijecnicki vjesnik.

[3]  A. Kausz,et al.  The Value of Vaccination in Chronic Kidney Disease , 2004, Seminars in dialysis.

[4]  A. Chin,et al.  Hepatitis B Virus Vaccine Response in Hemodialysis: Baseline Patient Characteristics , 2003, Hemodialysis international. International Symposium on Home Hemodialysis.

[5]  M. Goldstein,et al.  A randomized comparison of intradermal and intramuscular vaccination against hepatitis B virus in incident chronic hemodialysis patients. , 2000, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[6]  J. Brown,et al.  Improved hepatitis B vaccination rates in ESRD patients in California. , 2000, Advances in renal replacement therapy.

[7]  S. Sezer,et al.  Factors influencing response to hepatitis B virus vaccination in hemodialysis patients. , 2000, Transplantation proceedings.

[8]  J. Gonin.  Maintenance immunosuppression: new agents and persistent dilemmas. , 2000, Advances in renal replacement therapy.

[9]  A. Farghaly,et al.  Immune response to hepatitis B vaccine in haemodialysis patients. , 2000, The Journal of the Egyptian Public Health Association.

[10]  W. Urbanowicz.  [Efficacy of prophylactic vaccination against Hepatitis B Virus infection viruses in hemodialyzed patients]. , 2000, Przeglad epidemiologiczny.

[11]  C. Sabin,et al.  Contribution of human leukocyte antigens to the antibody response to hepatitis B vaccination. , 1997, Tissue antigens.

[12]  R. Peces,et al.  Prospective analysis of the factors influencing the antibody response to hepatitis B vaccine in hemodialysis patients. , 1997, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[13]  J. Montoliu,et al.  Response to the hepatitis B virus vaccine in haemodialysis patients: influence of malnutrition and its importance as a risk factor for morbidity and mortality. , 1996, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[14]  D. Marcelli,et al.  Recombinant hepatitis B vaccine use in chronic hemodialysis patients. Long-term evaluation and cost-effectiveness analysis. , 1996, Nephron.

[15]  G. Füst,et al.  Relationship Between the Reactivity to Hepatitis B Virus Vaccination and the Frequency of MHC Class I, II and III Alleles in Haemodialysis Patients , 1995, Scandinavian journal of immunology.

[16]  J. Teruel,et al.  Hepatitis C virus infection decreases the effective antibody response to hepatitis B vaccine in hemodialysis patients. , 1994, Clinical nephrology.

[17]  M. Buti,et al.  Long-term immunogenicity and efficacy of hepatitis B vaccine in hemodialysis patients. , 1992, American journal of nephrology.

[18]  R Williams,et al.  Hepatitis B vaccination. , 1997, The British journal of clinical practice.